Copyright
©The Author(s) 2022.
World J Gastroenterol. Mar 7, 2022; 28(9): 918-932
Published online Mar 7, 2022. doi: 10.3748/wjg.v28.i9.918
Published online Mar 7, 2022. doi: 10.3748/wjg.v28.i9.918
Figure 3 PI3K/AKT/NF-κB pathway was involved in hypoxia/reoxygenation-induced apoptosis.
A: Representative western blotting and quantification data for PI3K, p-AKTser473, p-AKTThr308, NF-κB P65, and β-actin at different time points after hypoxia/reoxygenation (H/R) treatment. ns, no significant difference, aP < 0.01 and bP < 0.001 vs control (n = 3); B: Representative images of immunofluorescence staining for NF-κB P65 in Caco2 cells before (Con) and after the H/R treatment at different time, Bars = 100-μm (n = 3); C: Representative Western blotting and quantification data for cell apoptotic proteins Bcl-2, and Bax after NF-κB inhibitor BAY11, AKT activator IGF-1 and PI3K activator 740 Y-P treatment, aP < 0.01 and bP < 0.001 vs control (n = 3); D: Representative Western blotting and quantification data for NF-κB P65 after AKT activator IGF-1 and PI3K activator 740 Y-P treatment, aP < 0.01 and bP < 0.001 vs control (n = 3); E: Representative Western blotting and quantification data for PI3K, p-AKTser473, and p-AKTThr308, after NF-κB inhibitor BAY11 treatment. Data are presented as mean ± SD. bP < 0.001 vs control (n = 3). NS: No significant difference.
- Citation: Dong ZW, Liu H, Su FF, Fan XZ, Zhang Y, Liu P. Cystic fibrosis transmembrane conductance regulator prevents ischemia/reperfusion induced intestinal apoptosis via inhibiting PI3K/AKT/NF-κB pathway. World J Gastroenterol 2022; 28(9): 918-932
- URL: https://www.wjgnet.com/1007-9327/full/v28/i9/918.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i9.918